Table 6

Treatment outcome

CCG, n = 197CALGB, n = 124PRHR
Complete remission, no. patients (%) 177 (90) 112 (90) .89  
7-y EFS, % (CI) 63 (55-72) 34 (24-44) < .001 2.2 (1.6-3.0) 
EFS by phenotype, % (CI)     
    B-lineage 54 (42-67) 37 (24-51) .03 1.6 (1.1-2.5) 
    T-lineage 65 (42-77) 37 (14-61) .08  
EFS by WBC, % (CI)     
    Less than 50 × 109/L 65 (56-75) 37 (26-48) < .001 2.2 (1.5-3.2) 
    More than 50 × 109/L 56 (38-74) 22 (5-40) .009 2.3 (1.2-4.2) 
7-y survival, % (CI) 67 (58-75) 46 (36-56) < .001 1.9 (1.3-2.7) 
CCG, n = 197CALGB, n = 124PRHR
Complete remission, no. patients (%) 177 (90) 112 (90) .89  
7-y EFS, % (CI) 63 (55-72) 34 (24-44) < .001 2.2 (1.6-3.0) 
EFS by phenotype, % (CI)     
    B-lineage 54 (42-67) 37 (24-51) .03 1.6 (1.1-2.5) 
    T-lineage 65 (42-77) 37 (14-61) .08  
EFS by WBC, % (CI)     
    Less than 50 × 109/L 65 (56-75) 37 (26-48) < .001 2.2 (1.5-3.2) 
    More than 50 × 109/L 56 (38-74) 22 (5-40) .009 2.3 (1.2-4.2) 
7-y survival, % (CI) 67 (58-75) 46 (36-56) < .001 1.9 (1.3-2.7) 
View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal